Explore why patients hesitate to switch to biosimilars despite proven safety and cost savings. Learn how education and transparency can bridge the knowledge gap and build trust in these innovative treatments.
Read MoreExplore how the FDA evaluates and lists biosimilars. Learn about the BPCIA pathway, the 'totality of evidence' approach, interchangeability standards, and where to find approval data in the Purple Book.
Read MoreBiologic drugs in the U.S. enjoy 12 years of market exclusivity before biosimilars can enter. This delay, enforced by law and patent strategies, keeps prices high and limits patient access. Here's how the system works-and why it's changing.
Read MorePharmacists play a critical role in biosimilar adoption by counseling patients, ensuring proper substitution, and navigating complex regulations. Learn how they drive cost savings and improve adherence in biologic therapy.
Read More
